PN 30X
Alternative Names: PN-30XLatest Information Update: 21 Feb 2023
At a glance
- Originator PAEAN Biotechnology
- Class Antineoplastics; Cell therapies; Immunoglobulin Fv fragments; Immunotherapies; Neuroprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; CNS disorders
Most Recent Events
- 21 Feb 2023 Preclinical trials in CNS disorders in South Korea (Parenteral)(PAEAN Biotechnology pipeline, February 2023)
- 12 Jul 2022 Preclinical trials in Breast cancer in South Korea (Parenteral)
- 09 Apr 2018 PAEAN Biotechnology has patent protection for method for transferring foreign mitochondria into cells in South Korea